摩根大通发表研究报告指，将亚盛医药(06855.HK) 目标价由93元下调至89元，续予“增持”评级。摩通预计，日本武田药品将不会在2027年前行使奥雷巴替尼(olverembatinib)的独家选择权。此外，该行假设慢性骨髓性白血病适应症将在2027年取得第三期临床试验数据，将其商业化时间推迟至2028年。该行表示，展望未来，奥雷巴替尼和lisaftoclax是具差异化且具备潜力的药品，将可成为...
Source Link摩根大通发表研究报告指，将亚盛医药(06855.HK) 目标价由93元下调至89元，续予“增持”评级。摩通预计，日本武田药品将不会在2027年前行使奥雷巴替尼(olverembatinib)的独家选择权。此外，该行假设慢性骨髓性白血病适应症将在2027年取得第三期临床试验数据，将其商业化时间推迟至2028年。该行表示，展望未来，奥雷巴替尼和lisaftoclax是具差异化且具备潜力的药品，将可成为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.